Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01302379 · ClinicalTrials.gov registry record · NA

Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors

A NA study, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
333
Enrollment target

NCT01302379: Completed NA study, sponsored by University of California, San Diego.

NCT01302379 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 333 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01302379, a NA study, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
333 participants
Enrollment target

Study Summary

This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle intervention and metformin (a drug used to treat diabetes) to investigate how these treatments, alone or in combination, affect biomarkers associated with breast cancer survival. The Reach for Health Study will enroll 340 overweight/obese, postmenopausal breast cancer survivors. After completing the screening process and baseline measures, participants will be randomized in equal numbers to: (1) placebo, (2) metformin, (3) lifestyle intervention and placebo, or (4) lifestyle intervention and metformin. The intervention was powered on the main effects and the planned analyses are to compare: Metformin to Placebo and a separate comparison of Lifestyle intervention to control. The interventions will last for 6 months. Concentrations of circulating biomarkers will be assessed at baseline and 6 months.

Primary Outcome

Insulin measured as percent change from baseline

Interventions

  • DRUG Placebo
  • DRUG Metformin
  • BEHAVIORAL Lifestyle intervention
  • BEHAVIORAL Standard printed dietary guidelines

Trial Details

FieldValue
Enrollment Target 333 participants
Start Date 2011-08
Est. Completion 2016-12
Phase NA
University of California, San Diego

775 total trials

What the finished NCT01302379 record still lists

NCT01302379 is an interventional study that assigns participants to a tested intervention. The registered 333 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT01302379 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01302379 about?

NCT01302379 is a clinical study titled "Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors". This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle intervention and metformin (a drug used to treat diabetes) to investigate how these treatments, alone or in combination, affect biomarkers associated with breast cancer survival. The Reach for Health Study wil...

What is the current status of trial NCT01302379?

This trial is currently completed. It is a NA study. The enrollment target is 333 participants. The study started on 2011-08. Estimated completion is 2016-12.

What interventions are being tested in trial NCT01302379?

The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Lifestyle intervention (BEHAVIORAL), Standard printed dietary guidelines (BEHAVIORAL).

Who is sponsoring clinical trial NCT01302379?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01302379's enrollment target sits among peer trials

333 306th of 2000 higher than 1,695 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07395687 · 333 participants · Phase 2

    A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

  • NCT05131672 · 334 participants · NA

    Cast or Operation for Medial Epicondyle Fracture Treatment in Children

  • NCT05131685 · 334 participants · NA

    Distal Radius Interventions for Fracture Treatment

  • NCT05546931 · 334 participants · NA

    Mobile Health Program for Rural Hypertension

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01302379, the US trial registry maintained by the National Library of Medicine. NCT01302379 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.